Navigation Links
Idenix Pharmaceuticals Prices Public Offering of Common Stock
Date:11/16/2011

CAMBRIDGE, Mass., Nov. 16, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 9,393,416 shares of its common stock at a public offering price of $6.50 per share. All of the shares are being sold by Idenix. The offering is expected to close on November 21, 2011, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering.  Idenix has granted the underwriter a 30-day option to purchase up to an additional 1,409,013 shares to cover over-allotments, if any.

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. Idenix will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.

MTS Securities, LLC provided financial advisory services to Idenix.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... VIEJO, Calif. , Feb. 12, 2016  Sequent ... enrollment in a study to evaluate the safety and ... for the treatment of ruptured intracranial aneurysms.  Prof ... University Hospital, in Paris, France ... first patient. France and ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not ... Peety PoppersTM series, sign language translation is featured in the top right of the ... Peety PoppersTM lessons has a sign language translator to teach kids the game and ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training ... exciting way to get fit and healthy. Located in Phoenixville, PA, the classes are ... class designed for horseback riders who want to lose weight and tone up. This ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
Breaking Medicine News(10 mins):